These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 31244581)
1. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform. Aleksandrova K; Leise J; Priesner C; Melk A; Kubaink F; Abken H; Hombach A; Aktas M; Essl M; Bürger I; Kaiser A; Rauser G; Jurk M; Goudeva L; Glienke W; Arseniev L; Esser R; Köhl U Transfus Med Hemother; 2019 Feb; 46(1):47-54. PubMed ID: 31244581 [TBL] [Abstract][Full Text] [Related]
2. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970 [TBL] [Abstract][Full Text] [Related]
3. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration. Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403 [TBL] [Abstract][Full Text] [Related]
4. Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. Aleksandrova K; Leise J; Priesner C; Aktas M; Apel M; Assenmacher M; Bürger I; Richter A; Altefrohne P; Schubert C; Holzinger A; Barden M; Bezler V; von Bergwelt-Baildon M; Borchmann P; Goudeva L; Glienke W; Arseniev L; Esser R; Abken H; Koehl U Front Immunol; 2024; 15():1328368. PubMed ID: 39386211 [TBL] [Abstract][Full Text] [Related]
5. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809 [TBL] [Abstract][Full Text] [Related]
6. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855 [TBL] [Abstract][Full Text] [Related]
7. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19 Teoh J; Brown LF Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089 [TBL] [Abstract][Full Text] [Related]
8. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A Front Immunol; 2019; 10():2361. PubMed ID: 31649672 [TBL] [Abstract][Full Text] [Related]
9. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R Front Immunol; 2022; 13():839783. PubMed ID: 35401506 [TBL] [Abstract][Full Text] [Related]
10. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M Front Immunol; 2020; 11():482. PubMed ID: 32528460 [TBL] [Abstract][Full Text] [Related]
11. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Palen K; Zurko J; Johnson BD; Hari P; Shah NN Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575 [TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms. Priesner C; Esser R; Tischer S; Marburger M; Aleksandrova K; Maecker-Kolhoff B; Heuft HG; Goudeva L; Blasczyk R; Arseniev L; Köhl U; Eiz-Vesper B; Klöß S Front Immunol; 2016; 7():393. PubMed ID: 27746781 [TBL] [Abstract][Full Text] [Related]
13. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167 [TBL] [Abstract][Full Text] [Related]
14. CAR-T cell expansion platforms yield distinct T cell differentiation states. Song HW; Prochazkova M; Shao L; Traynor R; Underwood S; Black M; Fellowes V; Shi R; Pouzolles M; Chou HC; Cheuk AT; Taylor N; Jin P; Somerville RP; Stroncek DF; Khan J; Highfill SL Cytotherapy; 2024 Jul; 26(7):757-768. PubMed ID: 38625071 [TBL] [Abstract][Full Text] [Related]
15. Automated, scaled, transposon-based production of CAR T cells. Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530 [TBL] [Abstract][Full Text] [Related]
16. Automated generation of gene-edited CAR T cells at clinical scale. Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430 [TBL] [Abstract][Full Text] [Related]
17. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System. Marín Morales JM; Münch N; Peter K; Freund D; Oelschlägel U; Hölig K; Böhm T; Flach AC; Keßler J; Bonifacio E; Bornhäuser M; Fuchs A Front Immunol; 2019; 10():38. PubMed ID: 30778344 [TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor. Machietto R; Giacobbe N; Perazzelli J; Hofmann TJ; Barz Leahy A; Grupp SA; Wang Y; Kadauke S J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607096 [TBL] [Abstract][Full Text] [Related]
19. Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. Joedicke JJ; Großkinsky U; Gerlach K; Künkele A; Höpken UE; Rehm A Mol Ther Methods Clin Dev; 2022 Mar; 24():181-198. PubMed ID: 35118163 [TBL] [Abstract][Full Text] [Related]
20. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. Palani HK; Arunachalam AK; Yasar M; Venkatraman A; Kulkarni U; Lionel SA; Selvarajan S; Korula A; Abraham A; George B; Adair JE; Orentas R; Dropulic B; Mathews V Bone Marrow Transplant; 2023 Feb; 58(2):160-167. PubMed ID: 36347999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]